Rhumbline Advisers lifted its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,686,571 shares of the biopharmaceutical company’s stock after buying an additional 68,390 shares during the quarter. Rhumbline Advisers owned about 0.16% of Bristol-Myers Squibb worth $164,633,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Vestpro Financial Partners Inc. dba CPF Texas bought a new position in shares of Bristol-Myers Squibb in the 4th quarter worth $196,000. Arizona State Retirement System lifted its holdings in shares of Bristol-Myers Squibb by 2.0% in the 4th quarter. Arizona State Retirement System now owns 414,679 shares of the biopharmaceutical company’s stock worth $25,412,000 after purchasing an additional 8,176 shares in the last quarter. State of Wisconsin Investment Board lifted its holdings in shares of Bristol-Myers Squibb by 14.9% in the 4th quarter. State of Wisconsin Investment Board now owns 2,243,873 shares of the biopharmaceutical company’s stock worth $137,505,000 after purchasing an additional 290,622 shares in the last quarter. MUFG Americas Holdings Corp lifted its holdings in shares of Bristol-Myers Squibb by 6.2% in the 4th quarter. MUFG Americas Holdings Corp now owns 341,302 shares of the biopharmaceutical company’s stock worth $20,915,000 after purchasing an additional 20,070 shares in the last quarter. Finally, Independence Bank of Kentucky bought a new position in shares of Bristol-Myers Squibb in the 4th quarter worth $781,000. 71.49% of the stock is owned by institutional investors.
A number of brokerages recently issued reports on BMY. Argus reiterated a “buy” rating and issued a $66.43 target price (down from $75.00) on shares of Bristol-Myers Squibb in a report on Wednesday. JPMorgan Chase & Co. set a $75.00 target price on Bristol-Myers Squibb and gave the stock an “overweight” rating in a report on Tuesday. TheStreet cut Bristol-Myers Squibb from a “b” rating to a “c+” rating in a report on Thursday, March 8th. ValuEngine cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Finally, Bank of America increased their target price on Bristol-Myers Squibb from $64.00 to $68.00 and gave the stock a “neutral” rating in a report on Monday, March 5th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $66.79.
Bristol-Myers Squibb stock opened at $66.10 on Thursday. Bristol-Myers Squibb Co has a 52 week low of $51.56 and a 52 week high of $70.05. The firm has a market capitalization of $108,452.49, a price-to-earnings ratio of 22.07, a price-to-earnings-growth ratio of 2.03 and a beta of 0.98. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period last year, the firm posted $0.63 EPS. The business’s revenue was up 3.9% compared to the same quarter last year. equities research analysts anticipate that Bristol-Myers Squibb Co will post 3.22 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.42%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 271.19%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.